Načítá se...
A comprehensive review of lenalidomide in B-cell non-Hodgkin lymphoma
Lenalidomide, an immunomodulatory drug that the US Food and Drug Administration (FDA) approved for the treatment of multiple myeloma, 5q- myelodysplasia and mantle-cell lymphoma (MCL), has encouraging efficacy in other B-cell malignancies. Its unique mechanism of action is in part due to altering th...
Uloženo v:
| Vydáno v: | Ther Adv Hematol |
|---|---|
| Hlavní autoři: | , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
SAGE Publications
2016
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4959641/ https://ncbi.nlm.nih.gov/pubmed/27493711 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2040620716652861 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|